Stable peptide solutions
Incorporating PVP stabilizes high-concentration peptide solutions, addressing aggregation and viscosity issues, enhancing safety and efficacy in ocular and subcutaneous administration.
Patent Information
- Application Number
- PCT/US2026/025719
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-04-29
- Publication Date
- 2026-11-12
AI Technical Summary
Peptide therapeutics face challenges with high concentration formulations due to aggregation, instability, and viscosity issues, which compromise safety and efficacy, particularly in ocular and subcutaneous administration.
Incorporating polyvinylpyrrolidone (PVP) with a weight average molecular weight of 2,000 to 360,000 g/mol at a peptide-to-PVP ratio of 1:1 to 10:1 stabilizes peptide solutions, reducing aggregation and maintaining low viscosity.
The formulations exhibit reduced peptide aggregation by up to 50% and low viscosity, ensuring stability over extended periods, suitable for high-concentration peptide administration.
Smart Images

Figure US2026025719_12112026_PF_FP_ABST
Abstract
Description
STABLE PEPTIDE SOLUTIONSCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 801,414 filed May 7, 2025, the entire contents of which are incorporated herein by reference.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing (339881004SEQ. xml; Size: 1,970 bytes; and Date of Creation: April 27, 2026), which has been submitted electronically in XML format, and is hereby incorporated by reference in its entirety.BACKGROUND OF THE DISCLOSURE
[0003] The present disclosure is directed to peptide formulations, and in particular, peptide solutions, comprising polyvinylpyrrolidone (PVP), that are stable, even at high peptide concentrations. The formulations are suitable for administration to a subject via a variety of routes, including ocular administration.
[0004] Peptides have emerged as a distinct therapeutic modality compared to typical small molecule drugs and large molecule proteins (Henninot, et al., “The Current State of Peptide Drug Discovery: Back to the Future?”, J. Med. Chem. 2018, 61, 1382-1414; Wang, et al., “Therapeutic Peptides: Current Applications and Future Directions,” Signal Transduct. Target. Ther. 2022, 7, 48; Lau, et al., “Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions,” Bioorg. Med. Chem.2018, 26, 2700-2707). However, peptide therapeutics exhibit unique challenges that make their successful development difficult. These can include pharmacokinetic liabilities such as short half-life and limited absorption across physiological barriers as well as poor stability (Di, L., “Strategic Approaches to Optimizing Peptide ADME Properties,” AAPS J. 2015, 17, 134-143).
[0005] In general, protein and peptide drug products are formulated at relatively low concentration for intravenous (IV) administration (Garidel, et al., “High-ConcentrationProtein Formulations: How High Is High?,” Eur. J. Pharm. Biopharm. 2017, 119, 353-360). On the other hand, subcutaneous (SC) or ocular administration would provide significant benefits to patients. However, SC injections or ocular administration options have limited dosing volume, potentially resulting in high peptide dose concentrations. This can result in significant challenges including high viscosity and / or physical instability leading to aggregation (Bak, et al., “Physicochemical and Formulation Developability Assessment for Therapeutic Peptide Delivery — A Primer,” Aaps J 2015, 17, 144-155; Evers, et al., “Peptide Optimization at the Drug Discovery-Development Interface: Tailoring of Physicochemical Properties Toward Specific Formulation Requirements,” J Pharm Sci 2019, 108, 1404-1414). Higher concentrations often exacerbate these effects and lead to increased risk of peptide-peptide interactions potentially leading to conformational changes, aggregation, precipitation, or gelation (Zapadka, et al., “Factors Affecting the Physical Stability (Aggregation) of Peptide Therapeutics,” Interface Focus 2017, 7, 20170030).
[0006] Peptide aggregation thus poses a significant risk in drug product development, as it can compromise both the safety and efficacy of the final therapeutic, particularly at high concentrations. It would thus be beneficial to provide stable peptide formulations that can be formulated at a high concentration, while minimizing the aggregation typically associated with such formulations.BRIEF DESCRIPTION OF THE DISCLOSURE
[0007] In one aspect, the disclosure is directed to a stable peptide solution formulation comprising: a peptide; and a polyvinylpyrrolidone (PVP) having a weight average molecular weight of from about 2,000 to about 360,000 g / mol, wherein the weight ratio of peptide to PVP is from about 1:1 to about 10:1.
[0008] In another aspect, the disclosure is directed to a method of administering a stable peptide solution formulation to a subject, comprising filling an implantable device with a formulation as described herein, and implanting the device into the subject.
[0009] Other aspects of the disclosure will be described herein.BRIEF DESCRIPTION OF THE DRAWINGS
[0010] FIG. 1 is an illustration of a disulfide constrained peptide (DCP) with a molecular weight of 3388 g / mol, used in Example 1.
[0011] FIG. 2 is an illustration of insulin with a molecular weight of 5808 g / mol, used in Example 1.
[0012] FIGs. 3A-3D are graphs depicting the aggregation levels of 100 mg / mL DCP in phosphate buffer with various levels of PVP types and concentrations. The stability of peptide formulations was measured by SEC for TO, T3, and T7 days and the formulations were incubated at 37°C, as described in Example 1. FIG. 3A - DCP with PVP K12; FIG.3B - DCP with PVP K17; FIG. 3C - DCP with PVP K25; FIG. 3D - DCP with PVP K30.
[0013] FIG. 4 is a graph depicting the aggregation levels of 100 mg / mL DCP in phosphate buffer with 10 mg / mL of PVP (10:1 ratios). The stability of peptide formulations was measured by SEC for TO, T3, and T7 days and the formulations were incubated at 37°C.
[0014] FIG. 5 is a graph depicting the aggregation levels of 100 mg / mL DCP in phosphate buffer with various levels of KI 7 from 1 to 5%. The stability of peptide formulations was measured by SEC up to 24 weeks and the formulations were incubated at 37C.DETAILED DESCRIPTION OF THE DISCLOSUREDefinitions
[0015] As used herein, the term "disulfide constrained peptide” or “DCP” refers to a peptide between 26-50 amino acids in length, where one of the disulfides penetrates the macrocycle which is formed by the two other disulfides and their interconnecting backbones, thereby yielding a characteristic knotted topology with multiple loops exposed on the surface. The loops are defined as the amino acid regions which flank the six conserved cysteine residues and are highly variable in nature.
[0016] A "subject," "patient," or an "individual" for purposes of formulation administration refers to any animal classified as a mammal, including humans, domestic andfarm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc. Preferably, the mammal is human.
[0017] An "effective amount" of a peptide formulation as disclosed herein is an amount sufficient to carry out a specifically stated purpose. An "effective amount" can be determined empirically and by known methods relating to the stated purpose. The term "therapeutically effective amount" refers to an amount of a peptide formulation as disclosed herein, effective to "treat" a disease or disorder in a mammal (such as a human patient).
[0018] As used herein, by "pharmaceutically acceptable" or "pharmacologically compatible" is meant a material that is not biologically or otherwise undesirable, e.g., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. Pharmaceutically acceptable carriers or excipients have preferably met the required standards of toxicological and manufacturing testing and / or are included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
[0019] Reference to "about" a value or parameter herein refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to "about" a value or parameter herein includes (and describes) aspects that are directed to that value or parameter per se. For example, description referring to "about X" includes description of "X."
[0020] It is understood that aspects and embodiments of the invention described herein include "comprising," "consisting," and "consisting essentially of aspects and embodiments.
[0021] All references cited herein, including patent applications and publications, are hereby incorporated by reference in their entirety.Stable Peptide Formulations
[0022] The present disclosure is directed to peptide formulations, and in particular, peptide solutions, that are stable, even at high peptide concentrations. More particularly, it has been discovered that inclusion of polyvinylpyrrolidone (PVP) into a peptide solutionCTformulation stabilizes the formulation, and results in a formulation with reduced peptide aggregation, even at high peptide concentrations, as compared to formulations containing no PVP. Because many peptides are sensitive to instability, and susceptible to aggregation, it is unexpected that such stable, high concentration peptide solutions could be formulated.
[0023] Thus, in one aspect, the disclosure is directed to a stable peptide solution formulation comprising: a peptide; and a polyvinylpyrrolidone (PVP) having a weight average molecular weight of from about 2,000 to about 360,000 g / mol, wherein the weight ratio of peptide to PVP is from about 1:1 to about 10:1. In one aspect, the stable peptide formulation of the present disclosure is a solution.
[0024] Polyvinylpyrrolidone (PVP) is available in various grades, including KI 2, K17, K25, and K30 (see Table 1 for details). It has now been discovered that in high concentration peptide formulations, PVP contributes to maintaining stability by preventing agglomeration when included at particular weight ratios.Table 1: - Exemplary types of PVP and molecular weight range
[0025] In one aspect, the PVP used in the formulations of the present disclosure has a weight average molecular weight of from about 2,000 to about 360,000 g / mol. In one aspect, the PVP has a weight average molecular weight of about 2,000 to about 54,000 g / mol. In one aspect, the PVP has a weight average molecular weight of about 7,000 to about 54,000 g / mol. In one aspect, the PVP has a weight average molecular weight of about 7,000 to about 40,000 g / mol. In one aspect, the PVP has a weight average molecular weight of about 2,000to about 3,000 g / mol. In one aspect, the PVP has a weight average molecular weight of about 7,000 to about 11,000 g / mol. In one aspect, the PVP has a weight average molecular weight of about 28,000 to about 34,000 g / mol. In one aspect, the PVP has a weight average molecular weight of about 44,000 to about 54,000 g / mol.
[0026] The amount of PVP in the formulations of the present disclosure will vary depending on the concentration of the peptide, but suitably formulations of the present disclosure comprise sufficient PVP to mitigate aggregation of the peptide at high concentrations. In one aspect, the weight ratio of peptide to PVP in the formulation of the present disclosure is from about 1:1 to about 10:1. In some aspects, the weight ratio of peptide to PVP in the formulation of the present disclosure is from about 1:1 to about 8:1, or from about 1 : 1 to about 4: 1 , or from about 1 : 1 to about 2: 1 , or from about 2: 1 to about 10:1, or from about 2: 1 to about 4:1.
[0027] In certain aspects, the formulations of the present disclosure may comprise PVP in an amount of at least about 1 mg / mL. In one aspect, the formulations of the present disclosure comprise PVP in an amount of from about 1 mg / mL to about 200 mg / mL, or from about 1 mg / mL to about 150 mg / mL, or from about 1 mg / mL to about 100 mg / mL, or from about 1 mg / mL to about 10 mg / mL, or from about 2.5 mg / mL to about 10 mg / mL, or from about 10 mg / mL to about 100 mg / mL, or from about 25 mg / mL to about 100 mg / mL. In one aspect, the formulation comprises PVP in an amount of about 1 mg / mL, or about 2 mg / mL, or about 2.5 mg / mL, or about 3 mg / mL, or about 4 mg / mL, or about 5 mg / mL, or about 6 mg / mL, or about 7 mg / mL, or about 8 mg / mL, or about 9 mg / mL, or about 10 mg / mL, or about 15 mg / mL, or about 20 mg / mL, or about 25 mg / mL, or about 30 mg / mL, or about 35 mg / mL, or about 40 mg / mL, or about 50 mg / mL, or about 75 mg / mL, or about 100 mg / mL, or about 150 mg / mL, or about 200 mg / mL.
[0028] As discussed herein and as demonstrated in the Examples, the formulations of the present disclosure are generally applicable to structurally diverse peptides. As used herein, the term “peptide” refers to molecules comprising between 2 and 50 amino acids and having a molecular weight ranging from about 0.5 kDa to about 100 kDa, including from about 1 kDa to about 50 kDa, or from about 1.2 kDa to about 7.0 kDa. The peptide present in a solution of the present disclosure may be any peptide including, but not limited to, macrocyclic peptides, disulfide-constrained peptides, monoclonal antibodies, and largepeptide hormones. In one particular aspect, the peptide is selected from the group consisting of insulin, cyclosporine A, glucagon, and disulfide constrained peptides. In one aspect, the peptide is insulin. In one aspect, the peptide is a disulfide-constrained peptide (DCP). Examples of suitable peptides are described in WO 2017 / 049009, which is herein incorporated by reference in its entirety.
[0029] In one aspect, the formulations of the present disclosure comprise a high concentration of peptide. It will be understood that a “high” concentration of peptide will vary, depending on the type of peptide present in the formulation. For purposes of the present disclosure, a formulation comprises a “high” concentration of peptide if at least 40% of the peptide present in the formulation aggregates after storage at 37°C for 7 days, as measured using size exclusion chromatography (as described in the examples) in the absence of PVP (i.e., if the formulation contains no PVP).
[0030] In one aspect, the formulation of the present disclosure comprises the peptide in an amount of at least about 2 mg / ml, or at least about 3.5 mg / ml or at least about 10 mg / ml, or at least about 50 mg / ml, or at least about 100 mg / ml, or at least about 150 mg / ml, or from about 2 to about 200 mg / ml, or from about 2 to about 10 mg / ml, or from about 3.5 to about 10 mg / ml, or from about 50 to about 150 mg / ml, or from about 10 to about 100 mg / ml, or about 3.5 mg / ml or about 10 mg / ml or about 100 mg / ml.
[0031] In one aspect, the peptide is insulin, and the formulation comprises at least about 2 mg / ml, or at least about 3.5 mg / ml, or at least about 10 mg / ml, or from about 2 to about 10 mg / ml or from about 3.5 to about 10 mg / ml, or about 10 mg / ml of the peptide. In one aspect, the peptide is a disulfide-constrained peptide, and the formulation comprises at least about 100 mg / ml, or about 100 mg / ml of the peptide. In one aspect, the peptide is glucagon, and the formulation comprises at least about 10 mg / ml or about 10 mg / ml of the peptide. In one aspect, the peptide is a monoclonal antibody, and the formulation comprises at least about 50 mg / ml, or at least about 100 mg / ml, or at least about 150 mg / ml, or from about 50 to about 150 mg / ml, or from about 100 to about 150 mg / ml of the peptide.
[0032] As discussed herein, the peptide formulations of the present disclosure advantageously are stable. As used herein, the term “stable” means the formulation has 30% or less peptide aggregation after storage at 37°C for 7 days, wherein the peptide aggregation is measured using size exclusion chromatography, according to the procedure described inthe examples. In one aspect, the peptide formulation of the present disclosure has 25% or less peptide aggregation after storage at 37°C for 7 days. In one aspect, the peptide formulation of the present disclosure has 20% or less peptide aggregation after storage at 37°C for 7 days. In one aspect, the peptide formulation of the present disclosure has 15% or less peptide aggregation after storage at 37°C for 7 days. In one aspect, the peptide formulation of the present disclosure has 10% or less peptide aggregation after storage at 37°C for 7 days. In such aspects, the peptide aggregation is measured using size exclusion chromatography, according to the procedure described in the examples.
[0033] In one aspect, the peptide formulation of the present disclosure exhibits reduced aggregation over extended storage periods. In one aspect, the peptide formulation of the present disclosure has 50% or less peptide aggregation after storage at 37°C for 24 weeks, or 40% or less peptide aggregation after storage at 37°C for 24 weeks, or 30% or less peptide aggregation after storage at 37°C for 24 weeks, or 25% or less peptide aggregation after storage at 37°C for 24 weeks, or 22% or less peptide aggregation after storage at 37°C for 24 weeks, wherein the peptide aggregation is measured using size exclusion chromatography, according to the procedure described in the examples.
[0034] In other aspects, the peptide formulations of the present disclosure are stable at room temperature (such as at about 20-25°C) for about 0.5 weeks, about 1.0 weeks, about 1.5 weeks, about 2.0 weeks, about 2.5 weeks, 3.5 weeks, about 4.0 weeks, about 1 month, about 2 months about 3 months, about 4 months about 5 months, about 6 months, or greater than 6 months, including any range in between these values. In certain embodiments, the peptide formulations of the present disclosure are stable under storage at about 37°C for about 0.5 weeks, about 1.0 weeks, about 1.5 weeks, about 2.0 weeks, about 2.5 weeks, 3.5 weeks, about 4.0 weeks, about 1 month, about 2 months about 3 months, about 4 months about 5 months, about 6 months, or greater than 6 months, including any range in between these values.
[0035] In one aspect, the peptide formulation of the present disclosure exhibits reduced fibrillation as compared to peptide formulations that do not contain PVP. As discussed in the examples, fibril formation can compromise both therapeutic efficacy and safety. Fibrillation involves the assembly of peptides into [S-shcct-rich amyloid structures,resulting in decreased solubility, altered bioactivity, and potential immunogenicity, so control of fibrillation is advantageous for formulation development.
[0036] It has now been discovered that inclusion of PVP in a high concentration peptide solution formulation prevents or reduces fibril formation. Thus, in one aspect, the peptide formulation of the present disclosure exhibits at least 40% fibrillation inhibition, as compared to a control peptide formulation comprising no PVP, after storage at 37°C for 3 days. In some aspects, the peptide formulation of present disclosure exhibits at least 40% fibrillation inhibition, as compared to a control peptide formulation comprising no PVP, after storage at 37°C for 7 days.
[0037] As discussed in the examples, the stable peptide formulations of the present disclosure advantageously exhibit low viscosity, and inclusion of PVP in the formulations does not adversely affect the syringeability or manufacturability of the formulations. Thus, in one aspect, the peptide formulations of the present disclosure have a viscosity of about 15 centipoise (cP) or less. In one aspect, the peptide formulations of the present disclosure have a viscosity of about 10 cP or less. In one aspect, the peptide formulations of the present disclosure have a viscosity of about 8 cP or less. In one aspect, the peptide formulations of the present disclosure have a viscosity of about 7 cP or less. In one aspect, the peptide formulations of the present disclosure have a viscosity of from about 1 to about 10 cP, or from about 1 to about 8 cp, or from about 2 to about 8 cP.
[0038] In another aspect, the disclosure further relates to a method for preparing a stable peptide formulation, the method comprising combining a peptide and a polyvinylpyrrolidone (PVP) having a weight average molecular weight of from about 2,000 to about 360,000 g / mol, wherein the weight ratio of peptide to PVP is from about 1:1 to about 10:1.Pharmaceutical Compositions
[0039] The present disclosure further provides pharmaceutical compositions or medicaments comprising a stable peptide formulation described herein, and at least one therapeutically inert excipient, as well as methods of using the peptide formulation to prepare such compositions and medicaments. One aspect, therefore, includes a pharmaceutical composition comprising a therapeutically effective amount of a stable peptide formulationof the present disclosure. A further aspect includes a pharmaceutical composition comprising a therapeutically effective amount of a stable peptide formulation of the present disclosure, together with a pharmaceutically acceptable excipient. In one example, a therapeutically effective amount of a stable peptide formulation of the present disclosure may be formulated by mixing with physiologically acceptable excipients, i.e., excipients that are non-toxic to subjects at the dosages and concentrations employed into a dosage form at ambient temperature and at the appropriate pH.
[0040] Compositions are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the severity of the disorder, the particular patient being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
[0041] A pharmaceutical composition comprising a stable peptide formulation of the disclosure may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.
[0042] In certain embodiments, pharmaceutical compositions are formulated in any conventional manner using one or more physiologically acceptable excipients and auxiliaries which facilitate processing of the peptide into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any pharmaceutically acceptable techniques and excipients are optionally used as suitable. Pharmaceutical compositions comprising a therapeutically effective amount a stable peptide formulation of the disclosure are manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
[0043] Suitable excipients include carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (e.g., liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecyl sulphate, polyoxysorbitan oleate), binders,synthetic and natural polymers (for example albumin), stabilizers (e.g., antioxidants, for example ascorbic acid), colorants (e.g., inorganic pigments, for example iron oxides) and taste and / or odour correctants, and are well known to those skilled in the art and are described in detail in, e.g., Ansel, H. C., et al., Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, R. C., Handbook of Pharmaceutical Excipients, Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers (e.g., sodium phosphate buffer), surfactants, lubricating agents, suspending agents, preservatives, opaquing agents, glidants, processing aids, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a stable peptide formulation of the disclosure) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).
[0044] In some aspects, the pharmaceutical composition of the disclosure is formulated for parental injection, including formulations suitable for bolus injection or continuous infusion. In specific embodiments, formulations for injection are presented in unit dosage form (e.g., in ampoules) or in multi-dose containers. Preservatives are, optionally, added to the injection formulations. In still other embodiments, the pharmaceutical compositions are formulated in a form suitable for parenteral injection as sterile solutions in oily or aqueous vehicles. Parenteral injection formulations optionally contain formulatory agents such as stabilizing and / or dispersing agents. In specific embodiments, pharmaceutical formulations for parenteral administration include aqueous solutions.
[0045] In some embodiments, pharmaceutical composition comprising a therapeutically effective amount of a stable peptide formulation of the disclosure illustratively takes the form of a liquid where the agents are present in solution.
[0046] Furthermore, useful pharmaceutical compositions optionally include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and trishy droxymethylaminome thane; and buffers such as citrate / dextrose, sodium bicarbonate andammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.
[0047] Additionally, useful compositions also, optionally, include one or more salts in an amount required to bring osmolality of the composition into an acceptable range. Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.
[0048] Other useful pharmaceutical compositions optionally include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.
[0049] Still other useful compositions include one or more surfactants to enhance physical stability or for other purposes. Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40.
[0050] Still other useful compositions include one or more antioxidants to enhance chemical stability where required. Suitable antioxidants include, by way of example only, ascorbic acid and sodium metabisulfite.
[0051] In certain embodiments, compositions are packaged in single-dose non-reclosable containers. Alternatively, multiple-dose reclosable containers are used, in which case it is typical to include a preservative in the composition.
[0052] In particular aspects, the stable peptide formulations of the present disclosure can be incorporated into a pharmaceutical composition for ocular administration, which may include a diluent or other additives commonly present in pharmaceutical compositions. In certain aspects, such compositions further comprise a pharmaceutically acceptable excipient. In certain embodiments the compositions may also contain, buffers,carriers, stabilizers, preservatives and / or bulking agents, to render the formulation suitable for administration to a patient (e.g., for ocular administration) to achieve a desired effect or result. In certain embodiments, the pharmaceutical composition comprises one or more permeability enhancers that permit the peptide to penetrate the cornea.
[0053] Examples of such permeability enhancers include, e.g., surfactants, bile acids, chelating agents, preservatives, cyclodextrins (i.e., cylindrical oligonucleotides with a hydrophilic outer surface and a lipophilic inner surface that form complexes with lipophilic drugs), etc. Such permeability enhancers increase chemical stability and bioavailability and decrease local irritation. In certain embodiments, a pharmaceutical composition provided herein additionally comprises agents that increase the absorption and distribution of peptides in various ocular compartments. In certain embodiments, a pharmaceutical composition provided herein comprises a cross-linked polyacrylic acid, which can enhance ocular bioavailability by virtue of its mucoadhesive properties. In certain embodiments, a pharmaceutical composition provided herein comprises a bioadhesive polymer.
[0054] In certain embodiments, a pharmaceutical composition provided herein is formulated as an in-situ gelling system, e.g., a viscous polymer-based liquid that exhibits sol- to-gel phase transition on the ocular surface due to change in a specific physicochemical parameter (ionic strength, temperature, pH, or solvent exchange) when the composition comes into contact with tear fluid. In certain embodiments, a pharmaceutical composition provided herein is formulated as an eye spray. In certain embodiments, a pharmaceutical composition provided is formulated as liposomes. In certain embodiments, a pharmaceutical composition provided herein is formulated as niosomes (i.e., non-ionic surfactant-based vesicles containing, e.g., cholesterol as an excipient). In certain embodiments, a pharmaceutical composition provided herein is formulated as pharmacosomes (i.e., vesicles formed by amphiphilic drugs). Further details regarding various ophthalmic pharmaceutical formulations are provided in, e.g., Gaikwad et al. (2013) Indo Amer JPharm Res. 3, 3216-3232; Achouri et al. (2012) Drug Dev Indust Pharm. 39, 1599- 1617; Lu (2010) Recent Pat Drug Deliv Formul. 4, 49-57; Baranowski et al. (2014) Sci World J. doi.org / 10.1155 / 2014 / 861904; Lang (1995) Adv Drug Deliv Rev. 16, 39-43; Short (2008) Toxicologic Path. 36, 49-62; and others.CTMethods of Administration
[0055] In one aspect, the present disclosure is directed to a method comprising administering to a subject, a stable peptide formulation as described herein. In certain embodiments, the subject is a mammal (e.g., human, non- human primate, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc.). In certain embodiments, the subject is a human. In certain embodiments, the subject is a clinical patient, a clinical trial volunteer, an experimental animal, etc.
[0056] A stable peptide formulation of the disclosure may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal, ocular, epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
[0057] In certain embodiments the stable peptide formulation of the present disclosure is administered to a subject, e.g., via injection, e.g., subconjunctival injection, intracorneal injection, or intravitreal injection. Administration in aqueous form is usual, with a typical volume of 20-150pl e.g. 40-60pl, or 50pl. Injection can be via a 30-gauge x 1 / 2-inch (12.7 mm) needle. In certain embodiments, the formulation is provided in a pre-filled sterile syringe ready for administration. In certain embodiments, the syringe has low silicone content or is silicone free. The syringe may be made of glass. Using a pre-filled syringe for delivery has the advantage that any contamination of the sterile antagonist solution prior to administration can be avoided. Pre-filled syringes also provide easier handling for the administering ophthalmologist. See, e.g., WO 2014 / 033184, Fagan et al. (2013) Clin Exp Ophthalmol. 41, 500-507; Avery et al. (2014) Retina. 34 Suppl 12, S1-S18; and Doshi et al. (2015) Seminar Ophthalmol. 26, 104-113 for further details regarding intravitreal administration.
[0058] In certain embodiments, the stable peptide formulation is administered topically, e.g. in form of eye drops. Additional details regarding topical drug delivery to the eye are found in, e.g., Loftsson et al. (2012) Acta Ophthalmologica. 90, 603-608; Patel et al. (2013) World J. Pharmacol. 2, 47-64; Freeman et al. (2009) Exp Rev Ophthalmol. 4, 59-64; and Boddu et al. (2014) Recent Patents on Drug Delivery and Formulation. 8, 27-36.
[0059] In certain embodiments, an intravitreal device is used to continuously deliver the stable peptide formulation into the eye. In certain embodiments, the formulation is administered via ocular insert (including, but not limited to, e.g., Ocuserts, Lactisers, Soluble Ocular Drug Inserts (SODIs), Minidiscs, contact lenses, fdms, fdter paper strips, artificial tear inserts, and collagen shields). See, e.g., Gaikwad et al. (2013) Indo Amer J Pharm Res. 3, 3216-3232). In certain embodiments, the formulation is administered as a slow-release depot, an ocular plug / reservoir, an ocular implant (such as a scleral or vitreal implant).
[0060] Various scleral and intravitreal delivery systems are known in the art. These delivery systems are typically non-biodegradable, and may be active or passive. For example, WO 2010 / 088548 describes a delivery system having a rigid body using passive diffusion to deliver a therapeutic agent. W O 2002 / 100318 discloses a delivery system having a flexible body that allows active administration via a pressure differential. Alternatively, active delivery can be achieved by implantable miniature pumps. An example for an intravitreal delivery system using a miniature pump to deliver a therapeutic agent is the Ophthalmic MicroPump System™ marketed by Replenish, Inc. which can be programmed to deliver a set amount of a therapeutic agent for a pre-determined number of times. In certain embodiments, the stable peptide formulation is encased in a small capsule-like container (e.g., a silicone elastomer cup). The container is usually implanted in the eye above the iris. The container comprises a release opening. Release of the formulation may be controlled by a membrane positioned between the formulation and the opening, or by means of a miniature pump connected to the container. Alternatively, the formulation may be deposited in a slow-release matrix that prevents rapid diffusion of the formulation out of the container. Preferably, the intravitreal device is designed to release the formulation at an initial rate that is higher in the first month. The release rate slowly decreases, e.g., over the course of the first month after implantation, to a rate that is about 50% less than the initial rate. The container may have a size that is sufficient to hold a supply of the formulation that lasts for about four to six months. Since a reduced dose of the formulation may be sufficient for effective treatment when administration is continuous, the supply in the container may last for one year or longer, preferably about two years, more preferably about three years. Because only a small surgery is required to implant a delivery system and intravitreal injections are avoided, patient compliance issues with repeated intravitreal injections can beavoided. Intravitreal concentrations of the formulation are reduced, and therefore the potential risk of side-effects from the formulation entering the circulation is decreased.
[0061] In certain embodiments, the stable peptide formulation is administered via iontophoresis. Iontophoresis is a noninvasive technique in which a small electric current is applied to enhance ionized drug penetration into tissue (see, e.g., Myles et al. (2005) Adv DrugDeliv Rev 57, 2063-79 and Eljarrat-B instock et al. (2006) J Controlled Release 110, 479-89). The drug is applied with an electrode carrying the same charge as the drug, and the ground electrode, which is of the opposite charge, is placed elsewhere on the body to complete the circuit. The drug serves as the conductor of the current through the tissue.
[0062] Additional details regarding administration of drug to the eye are provided in, e.g., Kuno et al. (20\ \) Polymers 3, 193-221; Short (2008) Toxicologic Path. 36, 49-62; Ghateet al. (2006) Expert Opin DrugDeliv 3, 275-87; Davis et al. (2004) Curr OpinMol Therap 6, 195-205; Gaudana et al. (2010) AAPS J. 12, 348-360; and others.
[0063] In one aspect, the present disclosure is directed to a method of administering a stable peptide solution as described herein to a subject, the method comprising filling an implantable device with a stable peptide formulation of the present disclosure, and implanting the device into the subject. In one aspect, the implantable device is selected from the group consisting of: an ocular insert, a slow-release depot, an ocular plug / reservoir, a nonbiodegradable ocular implant or a biodegradable ocular implant. In one aspect, the stable peptide formulation is released from the implantable device for at least 16 weeks, or for at least 24 weeks. In one aspect, the method further comprises refilling the device with the stable peptide formulation.Articles of Manufacture and Kits
[0064] In certain embodiments, provided is an article of manufacture containing a composition, e.g., a stable peptide formulation described herein, and materials useful for the treatment of a disease or disorder (e.g., an ocular disease or disorder) is provided. The article of manufacture can comprise a container comprising the peptide formulation of the present disclosure and a label or package insert on or associated with the container. The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage,administration, contraindications and / or warnings concerning the use of such therapeutic products. In one aspect, the label or package insert will further comprise instructions for administering the stable peptide formulation solution to the patient.
[0065] Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. In certain embodiments, the container holds a peptide formulation of the present disclosure, and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). In one aspect, the container may have a complete set of items needed to implant a slow release ocular or intraocular drug delivery system, including, but not limited to, injection devices, topical and injectable medications, surgical instruments, sutures and suturing needles, and eye covers. In certain embodiments, the container fold sterile unit-dose packages. Articles of manufacture and kits comprising combinatorial therapies described herein are also contemplated.
[0066] Package insert refers to instructions customarily included in commercial packages of therapeutic products that contain information about the indications, usage, dosage, administration, contraindications and / or warnings concerning the use of such therapeutic products. In certain embodiments, the package insert indicates the use of the peptide formulation, e.g., for ocular administration.EXAMPLESExample 1: Stability of PVP-Containing Peptide Formulations
[0067] Peptide aggregation poses a significant risk in drug product development, as it can compromise both the safety and efficacy of the final therapeutic. Aggregation may lead to reduced bioavailability, altered pharmacokinetics, and increased immunogenicity, potentially triggering unwanted immune responses in patients. Factors such as peptide sequence, concentration, pH, temperature, and formulation components can influence aggregation propensity. Notably, higher concentrations of peptide formulations can increase the risk of aggregation, making it a critical parameter to monitor during formulation development. During development, it is crucial to thoroughly evaluate aggregation behavior using analytical tools and stress testing, and to design formulations that mitigate this risk. Itwould thus be useful to address peptide aggregation early in the development process to help ensure product stability, quality, and regulatory compliance.
[0068] In this example, the ability of PVP to stabilize high concentration peptide solutions was evaluated.Peptide selection
[0069] Two model peptide compounds were selected. Peptide 1 was a disulfide-constrained peptide (referred to herein as “DCP”) composed of 30 amino acids, which demonstrates excellent solubility, reaching over 100 mg / mL in phosphate buffer. Peptide 1 is described in WO 2017 / 049009 (see SEQ ID NO: 145), which is herein incorporated by reference. Peptide 2 was insulin (SEQ ID NO: 1: FVNQHLCGSHLVEALYLVCGERGFFYTPKT), which exhibits higher solubility at lower pH levels; therefore, a concentration of 10 mg / mL in 0.01 N HC1 was chosen as the testing condition. For reference, concentrations of insulin exceeding 3.5 mg / mL are generally considered high concentration. The structures of DCP and insulin are set forth in FIGs. 1 and 2.Characterization Methods
[0070] Size Exclusion Chromatography: A size-exclusion chromatography (SEC) was conducted to measure high-molecular weight species (HMWs). For SEC experiments, the column employed was a Xbridge BEH 125 A column (7.8 x 150 mm, 3.5 pm) (Waters, Milford, MA, USA) to achieve optimal resolution between peptide monomers and multimers. An isocratic elution at a flow rate of 0.5 mL / min for 10 min with a mobile phase of 80 vol% 5 mM potassium phosphate buffer (pH 7.0) and 20 vol% ACN was used. The column thermostat and auto-sampler temperature were set at 30 °C and 10 °C, respectively. A detection wavelength of 214 nm was selected for quantifying aggregates.
[0071] Fibrillation: Fibrillation was measured by Thioflavin T (ThT) assay. It was conducted on a SpectraMax Microplate Reader (San Jose, CA, USA) under fluorescence mode (excitation: 450 nm, emission: 482 nm) using a black and flat-bottom 96-well plate. Insulin fibril standard stock was prepared by dissolving insulin at 10 mg / mL in a mixture of 0.01 M HC1 and 0.1 M NaCl, and incubating it at 37 °C in a water bath for 48 hours. TheCTfibril standard stock was then diluted with formulation buffer to the desired concentrations (0-9.4 pg / mL) to prepare working standards. After adding ThT (with a final concentration of 5 pM) to standards and samples, triplicate fluorescence measurements were done and fibril amounts of samples were then quantified against the insulin fibril working standards through linear regression.
[0072] Viscosity: Viscosity measurement was performed by using UCL Junior automated viscometer. The samples were measured at 25°C, shear rate of 5365 s’1.Experimental Design
[0073] Peptide 1 (DCP) and insulin were prepared at concentrations of 100 mg / mL in 60 mM sodium phosphate buffer and 10 mg / mL in 0.01 N HC1, respectively. High- concentration peptide solutions were formulated with varying peptide-to-PVP weight ratios of 1:1, 2:1, 4:1, and 10:1. Four different grades of polyvinylpyrrolidone (PVP) were used: K12 (MW 3,000-7,000), K17 (MW 10,000-17,000), K25 (MW 30,000-40,000), and K30 (MW 45,000-58,000). Each peptide-PVP formulation was incubated at 37 °C to evaluate stability. A control formulation without PVP was also included.
[0074] DCP study: The peptide concentration was maintained at 100 mg / mL to evaluate the impact of polyvinylpyrrolidone (PVP) on peptide stability. Four grades of PVP (K12, K17, K25, and K30) were individually combined with DCP across a concentration gradient ranging from 100 mg / mL to 10 mg / mL. A control sample without PVP was also included, resulting in a total of 17 formulations. Stability assessments were conducted at three time points: TO, T3 days, and T7 days. The study conditions are summarized in Table 2.Table 2: DCP peptide study conditionsTimepoint Concentration PVP Peptide:PVP (wt:wt) Diluent(days) (mg / mLO Excipient Ratio60 mM 1:1 (100 mg / mL PVP) K12, K17,TO, D3, D7 100 phosphate 2:1 (50 mg / mL PVP) K25, K30buffer 4:1 (25 mg / mL PVP)10:1 (10 mg / mL PVP)
[0075] Insulin study: In the insulin study, the peptide concentration was maintained at 10 mg / mL to evaluate the impact of polyvinylpyrrolidone (PVP) on peptide stability. Four grades of PVP, K12, K17, K25, and K30, were individually combined with insulin across a concentration gradient ranging from 10 mg / mL to 1 mg / mL. A control sample without PVP was also included, resulting in a total of 17 formulations. Stability assessments were conducted at three time points: TO and T7 days. The study conditions are summarized in Table 3.Table 3: Insulin peptide study conditionsTimepoint Concentration PVP Peptide:PVP (wt:wt)Diluent(days) (mg / mL) Excipient Ratio1:1 (10 mg / mL PVP ) K12, K17, 2:1 (5 mg / mL PVP)TO, D7 10 0.01 HC1K25, K30 4:1 (2.5mg / mL PVP)10:1 (1 mg / mL PVP)ResultsDCP Stability
[0076] SEC: In the absence of PVP, DCP exhibited a significant increase in aggregation levels, as measured by size-exclusion chromatography (SEC), rising from 2% at TO to 60% at T7 days. However, the inclusion of PVP effectively mitigated this aggregation, maintaining levels below 30% across all tested PVP grades (K12, K17, K25, and K30). Generally, increasing concentrations of PVP in the peptide formulation enhanced stability. At a 1:1 weight- to -weight ratio (100 mg / mL PVP), all formulations demonstrated less than 10% aggregation at Day 7. Conversely, lower PVP concentrations correlated with increased aggregation. For instance, at a 10:1 peptide-to-PVP ratio (10 mg / mL PVP), the aggregation levels increased, although they were still significantly lower than those of the control. Among the 10 mg / mL PVP group, PVP KI 2 exhibited slightly higher aggregation compared to the other grades. Still, it achieved over half of the peptide aggregation reduction relative to the control sample without PVP. These results are summarized in FIGs. 3A-3D.
[0077] To further evaluate the impact of different PVP types on peptide stability, formulations containing DCP at a 10:1 peptide-to-PVP weight ratio (10 mg / mL PVP) were assessed. At Day 7, the PVP KI 2 group exhibited 27% aggregation, whereas formulations with PVP grades K17, K25, and K30 demonstrated less than 20% aggregation. In contrast, the control group without PVP showed nearly 60% aggregation. These findings indicate that even at lower concentrations, PVP significantly reduces peptide aggregation, with higher concentrations offering enhanced stabilization. These results are shown in FIG. 4.
[0078] Peptide Fibrillation: Peptide fibrillation assessment is crucial in formulation development, as fibril formation can compromise both therapeutic efficacy and safety. Fibrillation involves the assembly of peptides into [S-shcct-rich amyloid structures, resulting in decreased solubility, altered bioactivity, and potential immunogenicity. Analytical techniques such as Thioflavin T fluorescence assays, circular dichroism spectroscopy, and electron microscopy are commonly employed to detect and characterize fibril formation. Early identification and control of fibrillation during formulation development are essential to ensure the production of stable and effective peptide therapeutics. The results suggested that the presence of PVP could also prevent the fibrillation event of high-concentration peptide formulations. For the DCP samples, it increased its fibrillation percentage to 0.27% after incubation at 37°C for 3 days (see Table 4). All the other groups, in the presence of PVP with concentration ranges from 100 to 10 mg / mL, showed a decreased potential for fibrillation. The higher concentrations present in the formulation further minimize the fibrillation amounts. Overall, K17, K25, and K30 demonstrated better protection compared to K12, which aligns with the SEC findings.Table 4: Fibrillation percentage of DCP at 100 mg / mL with various PVP types and ratios after incubation at 37°C for 3 daysFibril %Weight ratioof peptide to | K12 | K17 | K25 | K30 | Control |PVPF iTi0.270.11 0.09 0.09 0.08CTInsulin Stability
[0079] Peptide fibrillation: The fibrillation results for insulin were comparable to those observed with DCP. PVPs K17, K25, and K30 provided better stability protection than K12. Fibrillation formation was independent of K12 concentrations and resembled the control group. In contrast, the other PVP groups demonstrated a concentration-dependent effect on fibrillation control, with higher PVP ratios in the formulations leading to reduced fibrillation formation. The results are set forth in Table 5.Table 5: Fibrillation percentage of insulin at 10 mg / mL with various PVP types and ratios after incubation at 37C for 7 days
[0080] Viscosity: The viscosity measurement was intended to demonstrate that the ratio of PVP in the formulations does not adversely affect syringeability or manufacturability. Although high-viscosity formulations can pose developmental challenges, formulations with PVP concentrations from 1 mg / mL to 10 mg / mL of PVP still exhibited viscosities of less than 10 cP. The viscosity measurements for insulin formulations are set forth in Table 6.Table 6: Insulin with various levels and types of PVP does not significantly impact its viscosityWeight Ratio ofInsulin at 10 mg / mL peptide to PVP Viscosity (cP)Control 2.85K12 1:1 3.932:1 4.664:1 6.4510:1 4.16K17 1:1 3.162:1 4.424:1 4.7510:1 3.39K25 1:1 5.642:1 2.364:1 1.8110:1 3.32K30 1:1 7.062:1 5.184:1 5.5210:1 3.51Example 2: Use of PVP-Peptide Formulations in a Port Delivery SystemCT
[0081] In this example, the feasibility of using PVP -peptide formulations in a port delivery system was evaluated.Introduction
[0082] The Port Delivery System (PDS) is a refillable implant designed for ocular delivery, approximately the size of a grain of rice. It is surgically inserted into the pars plana of the eye, enabling continuous delivery of a customized formulation over time. Using a non-invasive procedure, the proprietary refill needle can extract 97% of the old content and simultaneously refill 100% of the new drug. PDS has been implemented with ranibizumab (Lucentis™) to treat wet age-related macular degeneration (AMD) and other vascular endothelial growth factor (VEGF)-related disorders. It can hold approximately 20 pL of a highly concentrated formulation and support 4-6 months of sustained release delivery in clinical trials. However, 20% of AMD patients do not respond to ranibizumab. Studies have shown that even highly concentrated ranibizumab in PDS does not reach the same Cmax as ranibizumab administered via intravitreal injection (IVT).
[0083] To address this obstacle, disulfide-constrained peptide (DCP) was introduced as a new modality. The unique scaffold of DCP is highly soluble and stable. Peptides offer a size advantage over antibodies — the molecular weight of DCP is 16-fold lower than ranibizumab — which allows for increased PDS load capacity and enhanced efficacy. In this example, a DCP with a molecular weight of 3 kDa that binds with high affinity to all VEGF-A isoforms was selected. With its potency and high molar doses, it has the potential to be effective for 10-month dosing.
[0084] Polymers such as polyvinylpyrrolidone (PVP) and poloxamers are known for their good solubility and ability to enhance sustained drug release in oral formulations. These excipients were investigated in an 8-day rabbit tolerability study. Among them, a novel ocular excipient, Kollidon 17 (KI 7), was identified and will be used to further study the release and stability of DCP formulations in the PDS over 24 weeks.Experimental Design
[0085] Port Delivery System (PDS) devices were filled with test formulations. The formulations consisted of DCP dissolved at 100 mg / mL in 60 mM Phosphate as a control, or100 mg / mL of DCP in varying concentrations of K17 (1%, 2.5%, and 5%). The assembled devices were then placed into 1.5 mL Eppendorf tubes containing 300 pL of release media. The media used for this study was Phosphate Buffered Saline at pH 7.2 with 0.01% Tween 20 and 0.02% Sodium Azide (PBS-TN). Once the devices were placed into these tubes, they were sealed to prevent evaporation and labeled appropriately. Samples were then transferred to a temperature-controlled chamber set at 37°C. Six implants were tested per study group (n=6).
[0086] At each time point, samples were removed from the chamber to transfer the devices to new Eppendorf tubes. Fresh release media (300 pL of PBS-TN) was added to each new tube, and each device was transferred from the old tubes to the new tubes. These new Eppendorf tubes were then placed back into the 37°C chamber for storage until the next sampling time point.
[0087] Released Sample Analytical Method: After removing the devices from the old tubes, an aliquot of the spent release media was taken and diluted 1:1 in an ACN: Water (30:70) solution in HPLC vials. The vials were then analyzed using HPLC to assess the amount of physical and chemical degradation, utilizing size-exclusion chromatography (SEC) and reverse-phase chromatography (RP-LC) methods.Results
[0088] High concentration DCP formulations have a significant tendency to form aggregates, posing risks to both safety and potency. This aggregation can be better controlled by incorporating appropriate excipients into the formulation. The DCP formulation is set at 100 mg / mL concentration for 24 weeks of release assessment. For the peptide formulation in the absence of PVP K17, it reached to 61.8% aggregation at week 24. For the formulations in the presence of KI 7, it helped preserve the stability. The aggregation were 45.8% for 1% K17 (10 mg / mL of PVP K17), 29.7% for 2.5% K17 (25 mg / mL of K17), and 21.5% for 5% K17 (50 mg / mL of K17). The results are set forth in FIG. 5.
[0089] This written description uses examples to disclose the invention, including the best mode, and also to enable any person skilled in the art to practice the invention, including making and using any devices or systems and performing any incorporated methods. The patentable scope of the invention is defined by the claims, and may includeother examples that occur to those skilled in the art. Such other examples are intended to be within the scope of the claims if they have structural elements that do not differ from the literal language of the claims, or if they include equivalent structural elements with insubstantial differences from the literal languages of the claims.
Claims
WHAT IS CLAIMED IS:
1. A stable peptide solution formulation comprising:a peptide; anda polyvinylpyrrolidone (PVP) having a weight average molecular weight of from about 2,000 to about 360,000 g / mol,wherein the weight ratio of peptide to PVP is from about 1:1 to about 10:1.
2. The formulation of claim 1, wherein the weight ratio of peptide to PVP is from about 1:1 to about 8:1.
3. The formulation of claim 1, wherein the weight ratio of peptide to PVP is from about 1 : 1 to about 4:1.
4. The formulation of claim 1, wherein the weight ratio of peptide to PVP is from about 1 : 1 to about 2:1.
5. The formulation of any one of claims 1-4, wherein the polyvinylpyrrolidone has a weight average molecular weight of from about 2,000 to about 54,000 g / mol.
6. The formulation of claim 5, wherein the polyvinylpyrrolidone has a weight average molecular weight of about 7,000 to about 54,000 g / mol.
7. The formulation of claim 6, wherein the polyvinylpyrrolidone has a weight average molecular weight of about 7,000 to about 40,000 g / mol.
8. The formulation of claim 7, wherein the polyvinylpyrrolidone has a weight average molecular weight of from about 7,000 to about 11,000 g / mol.
9. The formulation of any one of claims 1-8, comprising the PVP in an amount of at least about 1 mg / mL.
10. The formulation of claim 9, comprising the PVP in an amount of from about 1 mg / mL to about 200 mg / mL.CT11. The formulation of claim 10, comprising the PVP in an amount of from about 1 mg / mL to about 150 mg / mL.
12. The formulation of claim 11, comprising the PVP in an amount of from about 1 mg / mL to about 100 mg / mL.
13. The formulation of claim 12, comprising the PVP in an amount of from about 1 mg / mL to about 10 mg / mL.
14. The formulation of claim 13, comprising the PVP in an amount of from about 2.5 mg / mL to about 10 mg / mL.
15. The formulation of claim 12, comprising the PVP in an amount of from about 10 mg / mL to about 100 mg / mL.
16. The formulation of claim 15, comprising the PVP in an amount of from about 25 mg / mL to about 100 mg / mL.
17. The formulation of any one of claims 1-16, wherein the formulation comprises at least about 2 mg / ml of the peptide.
18. The formulation of claim 17, wherein the formulation comprises at least about 3.5 mg / mL of the peptide.
19. The formulation of claim 18, wherein the formulation comprises at least about 10 mg / mL of the peptide.
20. The formulation of any one of claims 17-19, wherein the peptide is insulin.
21. The formulation of any one of claims 1-16, wherein the formulation comprises at least about 100 mg / mL of the peptide.
22. The formulation of claim 21, wherein the peptide is a disulfide constrained peptide.
23. The formulation of any one of claims 1-22, wherein the formulation has a viscosity of about 15 cP or less.
24. The formulation of claim 23, wherein the formulation has a viscosity of about 10 cP or less.
25. The formulation of claim 24, wherein the formulation has a viscosity of about 8 cP or less.
26. The formulation of claim 25, wherein the formulation has a viscosity of from about 2 cP to about 8 cP.
27. The formulation of any one of claims 1-26, wherein the formulation has 30% or less peptide aggregation after storing at 37C for 7 days.
28. The formulation of claim 27, wherein the formulation has 20% or less peptide aggregation after storing at 37C for 7 days.
29. The formulation of any one of claims 1-28, wherein the formulation has 50% or less peptide aggregation after storing at 37C for 24 weeks.
30. The formulation of any one of claims 1-29, further comprising a diluent.
31. A method of administering a stable peptide solution formulation to a subject, comprising filling an implantable device with the formulation of any one of claims 1-30, and implanting the device into the subject.
32. The method of claim 31, wherein the implantable device is selected from the group consisting of: an ocular insert, a slow-release depot, an ocular plug / reservoir, a nonbiodegradable ocular implant or a biodegradable ocular implant.
33. The method of claim 32, wherein the formulation is released from the implantable device for at least 16 weeks.CT34. The method of claim 33, wherein the formulation is released from the implantable device for at least 24 weeks.
35. The method of any one of claims 31-34, further comprising refilling the device with the formulation.
